Список литературы

1. Богомильский М.Р. Детская оториноларингология: Руководство для врачей/Под ред. М.Р. Богомильского и В.Р. Чистяковой. В двух томах. Т. 1. М.: ОАО "Издательство "Медицина", 2005. 660 с.: ил.

2. Васильев А.Г., Хайцев Н.В., Балашов А.Л., Балашов Л.Д., Кравцова А.А., Трашков А.П., Пахомова М.А. О патогенезе синдрома острой кровопотери. Педиатр. 2019; 10(3): 93 - 100.

3. Волков А.Г., Бойко Н.В., Киселев В.В. Носовое кровотечение. - М.: АПП "Джангар", 2002. 276 с., ил.

4. Довгалюк А.Ю. Носовые кровотечения в структуре патологии лор-стационара/А.Ю. Довгалюк, Ш.М. Исмагилов, И.Ш. Гайнутдинов//Российская ринология. - 2011. - Т. 19, N 2. - С. 65 - 66. - EDN TJGBSB.

5. Ивойлов А.Ю. Современные методы остановки носовых кровотечений у детей/А.Ю. Ивойлов [и др.]//Практика педиатра. 2023. N 3. С. 19 - 26.

6. Крюков А.И., Товмасян А.С., Шведов Н.В., Кишиневский А.Е., Мосин В.В. Сравнение различных видов тампонады полости носа после эндоназальных хирургических вмешательств. Вестник оториноларингологии. 2024. Т. 89. N 4. С. 101.

7. Крюков А.И. Спонтанные носовые кровотечения: методы создания гемостаза. Учебно-методическое пособие N 37. Крюков А.И., Плавунов Н.Ф. и др. - Москва. 2024. 24 с.

8. Оториноларингология: Национальное руководство/Н.А. Дайхес, Ю.К. Янов [и др.]. - Москва 2024.

9. Пискунов С.З. Руководство по ринологии/Под ред. Г.З. Пискунова, С.З. Пискунова. - М.: Литтерра, 2011. 960 с.

10. Пшениснов К.В., Александрович Ю.С. Массивная кровопотеря в педиатрической практике. Гематология и трансфузиология. 2020; 65(1): 70 - 86.

11. Товмасян А.С. Наследственная геморрагическая телеангиэктазия (синдром Рандю-Ослера)/А. С. Товмасян, В.В. Мосин, Е.В. Носуля [и др.]//Вестник оториноларингологии. - 2022. - Т. 87, N 5. - С. 86 - 91. - DOI 10.17116/otorino20228705186. - EDN FXTCPO.

12. Файзулина Р.А. Этиологические причины и тактика диагностики кровотечений у детей: учебное пособие/Р.А. Файзуллина, О.И. Пикуза, А.М. Закирова. - Казань: КГМУ, 2015. - 76 с.

13. Царапкин Г.Ю. Коморбидный фон и оценка летальности, связанной с носовыми кровотечениями/Г. Ю. Царапкин, Н. Л. Кунельская, Н. Ф. Плавунов [и др.]//Российская ринология. - 2022. - Т. 30, N 1. - С. 33 - 39. - DOI 10.17116/rosrino20223001133. - EDN NIEIQH.

14. Ando Y., Iimura J., Arai S., et al. Risk factors for recurrent epistaxis: importance of initial treatment. Auris Nasus Larynx. 2014; 41: 41 - 45.

15. Bahit M.C., Lopes R.D., Wojdyla D.M., et al. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart. 2017; 103: 623 - 628.

16. Baugh, T. P., & Chang, C. W. D. (2018). Epidemiology and Management of Pediatric Epistaxis. Otolaryngology--head and neck surgery: official journal of American Academy of Otolaryngology-Head and Neck Surgery, 159(4), 712 - 716.

17. Bequignon E., Verillaud B., Robard L., et al. Guidelines of the French Society of Otorhinolaryngology (SFORL): first-line treatment of epistaxis in adults. Eur Ann Otorhinolaryngol Head Neck Dis. 2017; 134: 185 - 189.

18. BMJ. Best practice in epistaxis. https://bestpractice.bmj.com/topics/en-gb/421. Published 2017. Accessed November 7, 2018.

19. Shay S., Shapiro N.L., Bhattacharyya N., Epidemiological characteristics of pediatric epistaxis presenting to the emergency department, International Journal of Pediatric Otorhinolaryngology (2017), doi: 10.1016/j.ijporl.2017.10.026

20. Burton M.J., Interventions for Recurrent Idiopathic Epistaxis in Children.//Cochrane Database Syst Rev. 2004. N 1. CD004461

21. Cetinkaya E.A., Arslan I.B., Cukurova I. Nasal foreign bodies in children: types, locations, complications and removal. Int J Pediatr Otorhinolaryngol. 2015; 79: 1881 - 1885.

22. Chiu T.W., McGarry G.W. Prospective clinical study of bleeding sites in idiopathic adult posterior epistaxis. J Otolaryngol Head Neck Surg. 2007; 137: 390 - 393.

23. Chong L.Y., Head K., Hopkins C., Philpott C., Schilder A.G., Burton M.J. Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016; (4): CD011996.

24. Civelek B., Kargi A.E., Sensoz O., Erdogan B. Rare complication of nasal packing: alar region necrosis. Otolaryngol Head Neck Surg. 2000; 123: 656 - 657.

25. Davies K., Batra K., Mehanna R. et al. Pediatric epistaxis: Epidemiology, management & impact on quality of life, Int. J. Pediatr. Otorhinolaryngol. (2014), http://dx.doi.org/10.1016/j.ijporl.2014.05.013

26. Delaney M., Wendel S., Bercovitz R.S., et al. Transfusion reactions: prevention, diagnosis, and treatment. Lancet. 2016; 388: 2825 - 2836.

27. Denas G., Marzot F., Offelli P., et al. Effectiveness and safety of a management protocol to correct over-anticoagulation with oral vitamin K: a retrospective study of 1,043 cases. J Thromb Thrombolysis. 2009; 27: 340 - 347.

28. Denholm S.W., Maynard C.A., Watson H.G. Warfarin and epistaxis-a case controlled study. J Laryngol Otol. 1993; 107: 195 - 196.

29. Dokuyucu R., Gokce H., Sahan M., et al. Systemic side effects of locally used oxymetazoline. Int J Clin Exp Med. 2015; 8: 2674 - 2678.

30. Doo G., Johnson D.S. Oxymetazoline in the treatment of posterior epistaxis. Hawaii Med J. 1999; 58: 210 - 212.

31. Dubel G.J., Ahn S.H., Soares G.M. Transcatheter embolization in the management of epistaxis. Semin Intervent Radiol. 2013; 30: 249 - 262.

32. Fortin M., Bravo G., Hudon C. et al. Prevalence of multimorbidity among adults seen in family practice. Annals of Family Medicine. 2005; 3: 223 - 228. https://doi.org/10.1370/afm.272

33. Garcia Callejo F.J., Becares M.C., Calvo G.J., Martinez B.P., Marco S.M., Marco A.J. Epistaxis and dabigatran, a new non-vitamin K antagonist oral anticoagulant. Acta Otorrinolaringol Esp. 2014; 65: 346 - 354.

34. Goljo E., Dang R., Iloreta A.M., Govindaraj S. Cost of management in epistaxis admission: impact of patient and hospital characteristics. Laryngoscope. 2015; 125: 2642 - 2647.

35. Gottlieb M., DeMott J.M., Peksa G.D. Topical tranexamic acid for the treatment of acute epistaxis: a systematic review and meta-analysis. Ann Pharmacother. 2019; 53: 652 - 657.

36. Gremmel T., Panzer S. Oral antiplatelet therapy: impact for transfusion medicine. Vox Sang. 2017; 112: 511 - 517.

37. Hajimaghsoudi M, Largani H.A., Baradaranfar M.H., Aghabagheri M., Jafari M.A., Saeedi M. A novel method for epistaxis management: randomized clinical trial comparing nose clip with manual compression. Am J Emerg Med. 2018; 36: 149 - 150.

38. Halderman A.A., Ryan M.W., Clark C., et al. Medical treatment of epistaxis in hereditary hemorrhagic telangiectasia: an evidence-based review. Int Forum Allergy Rhinol. 2018; 8: 713 - 728.

39. Haraguchi H., Ebihara S., Saikawa M., Mashima K., Haneda T., Hirano K. Malignant tumors of the nasal cavity: review of a 60-case series. Jpn J Clin Oncol. 1995; 25: 188 - 194.

40. Khan M., Conroy K., Ubayasiri K., et al. Initial assessment in the management of adult epistaxis: systematic review. J Laryngol Otol. 2017; 131: 1035 - 1055.

41. Khan M., Conroy K., Ubayasiri K., et al. Initial assessment in the management of adult epistaxis: systematic review. J Laryngol Otol. 2017; 131: 1035 - 1055.

42. Khan M.K., Reda El., Badawey M., Powell J., Idris M. The utility of FloSeal haemostatic agent in the management of epistaxis. J Laryngol Otol. 2015; 129: 353 - 357

43. Kitamura T., Takenaka Y., Takeda K., et al. Sphenopalatine artery surgery for refractory idiopathic epistaxis: systematic review and meta-analysis. Laryngoscope. 2019; 129: 1731 - 1736.

44. Klossek J.M., Dufour X., de Montreuil C.B., et al. Epistaxis and its management: an observational pilot study carried out in 23 hospital centres in France. Rhinology. 2006; 44: 151 - 155.

45. Korkmaz H., Yao W.C., Korkmaz M., Bleier B.S. Safety and efficacy of concentrated topical epinephrine use in endoscopic endonasal surgery. Int Forum Allergy Rhinol. 2015; 5: 1118 - 1123.

46. Krempl G.A., Noorily A.D. Use of oxymetazoline in the management of epistaxis. Ann Otol Rhinol Laryngol. 1995; 104: 704 - 706

47. Kumar S., Shetty A., Rockey J., Nilssen E. Contemporary surgical treatment of epistaxis: what is the evidence for sphenopalatine artery ligation? Clin Otolaryngol Allied Sci. 2003; 28: 360 - 363.

48. Lasjaunias P., Marsot-Dupuch K., Doyon D. The radio-anatomical basis of arterial embolisation for epistaxis. J Neuroradiol. 1979; 6: 45 - 53.

49. Leung R.M., Smith T.L., Rudmik L. Developing a laddered algorithm for the management of intractable epistaxis: a risk analysis. JAMA Otolaryngol Head Neck Surg. 2015; 141: 405 - 409.

50. Li T., Li F., Cha X., Wang S., Yan J., Wang T., Liang C., Zhuang C., Ren W., Liu H. A Systematic Review and Meta-analysis of the Effects of Topical Tranexamic Acid versus Topical Vasoconstrictors on the Management of Epistaxis. Curr Pharm Des. 2023; 29(19): 1497 - 1503. doi: 10.2174/1381612829666230214093136.

51. Lopez F., Triantafyllou A., Snyderman C.H., et al. Nasal juvenile angiofibroma: current perspectives with emphasis on management. Head Neck. 2017; 39: 1033 - 1045.

52. Mattoo O., Yousuf A., Mir A., Muzaffar R., Pampori R. Control of anterior epistaxis: a comparative analysis of the decongestive effect of xylometazoline and adrenaline in idiopathic epistaxis in emergency settings. Clinical Rhinology. 2011; 4: 130 - 135.

53. McClurg S.W., Carrau R. Endoscopic management of posterior epistaxis: a review. Acta Otorhinolaryngol Ital. 2014; 34: 1 - 8.

54. McLeod R.W.J., Price A., Williams R.J., Smith M.E., Smith M., Owens D. Intranasal cautery for the management of adult epistaxis: systematic review. J Laryngol Otol. 2017; 131: 1056 - 1064.

55. Montastruc F., Montastruc G., Taudou M.J., Olivier-Abbal P., Montastruc J.L., Bondon-Guitton E. Acute coronary syndrome after nasal spray of oxymetazoline. Chest. 2014; 146: e214 - e215.

56. Moumoulidis I., Draper M.R., Patel H., Jani P., Price T. A prospective randomised controlled trial comparing Merocel and Rapid Rhino nasal tampons in the treatment of epistaxis. Eur Arch Otorhinolaryngol. 2006; 263: 719 - 722.

57. Murray S., Mendez A., Hopkins A., El-Hakim H., Jeffery C.C., D.W.J. Management of persistent epistaxis using floseal hemostatic matrix vs traditional nasal packing: a prospective randomized control trial. J Otolaryngol Head Neck Surg. 2018; 47: 3.

58. National ENT Trainee Research Network. Epistaxis 2016: national audit of management. J Laryngol Otol. 2017; 131: 1131 - 1141

59. Neil McIntosh, Jacqueline Y.Q.M., Adrian M. Epidemiology of Oronasal Hemorrhage in the First 2 Years of Life: Implications for Child Protection. Pediatrics November 2007; 120 (5): 1074 - 1078. 10.1542/peds. 2007 - 2097

60. Pierucci P., Lenato G.M., Suppressa P., et al. A long diagnostic delay in patients with hereditary haemorrhagic telangiectasia: a questionnaire-based retrospective study. Orphanet J Rare Dis. 2012; 7: 33.

61. Pletcher S.D., Metson R. Endoscopic ligation of the anterior ethmoid artery. Laryngoscope. 2007; 117: 378 - 381.

62. Rhinitis and epistaxis in patients treated by anti-angiogenic therapy/V. Pruli re-Escabasse et al.//Invest New Drugs. 2009. Vol. 27. P. 285 - 286

63. Rudmik L., Smith T.L. Management of intractable spontaneous epistaxis. Am J Rhinol Allergy. 2012; 26: 55 - 60.

64. Safety and Efficacy of Blue Light Laser Treatment in Hereditary Hemorrhagic Telangiectasia/DOI 10.1002/lsm.23289/Mattis Bertlich, Lasers in Surgery and Medicine, 2020

65. Sanders Y.V., Fijnvandraat K., Boender J., et al. Bleeding spectrum in children with moderate or severe von Willebrand disease: relevance of pediatric-specific bleeding. Am J Hematol. 2015; 90: 1142 - 1148.

66. Schaitkin B., Strauss M., Houck JR. Epistaxis: medical versus surgical therapy. A comparison of efficacy, complications, and economic considerations. Laryngoscope. 1987; 97: 1392 - 1396.

67. Schwartz R.H., Estroff T., Fairbanks D.N., Hoffmann N.G. Nasal symptoms associated with cocaine abuse during adolescence. Arch Otolaryngol Head Neck Surg. 1989; 115: 63 - 64.

68. Shargorodsky J., Bleier B.S., Holbrook E.H., et al. Outcomes analysis in epistaxis management: development of a therapeutic algorithm. Otolaryngol Head Neck Surg. 2013; 149: 390 - 398.

69. Shovlin C.L., Guttmacher A.E., Buscarini E., et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 2000; 91: 66 - 67.

70. Strach K., Schrock A., Wilhelm K., et al. Endovascular treatment of epistaxis: indications, management, and outcome. Cardiovasc Intervent Radiol. 2011; 34: 1190 - 1198.

71. Thiele B., Abdel-Aty Y., Marks L., Lal D., Marino M. Sclerotherapy for Hereditary Hemorrhagic Telangiectasia-Related Epistaxis: A Systematic Review. Ann Otol Rhinol Laryngol. 2023 Jan; 132(1): 82 - 90

72. Toner J.G., Walby A.P. Comparison of electro and chemical cautery in the treatment of anterior epistaxis. J Laryngol Otol. 1990; 104: 617 - 618.

73. Tunkel D.E., Anne S., Payne S.C., Ishman S.L., Rosenfeld R.M., Abramson P.J., Alikhaani J.D., Benoit M.M., Bercovitz R.S., Brown M.D., Chernobilsky B., Feldstein D.A., Hackell J.M., Holbrook E.H., Holdsworth S.M., Lin K.W., Lind M.M., Poetker D.M., Riley C.A., Schneider J.S., Seidman M.D., Vadlamudi V., Valdez T.A., Nnacheta L.C., Monjur T.M. Clinical Practice Guideline: Nosebleed (Epistaxis). Otolaryngol Head Neck Surg. 2020 Jan; 162(1_suppl): S1 - S38. doi: 10.1177/0194599819890327. PMID: 31910111.

74. Zahed R., Mousavi J.M.H., Naderi A., Naderpour Z., Saeedi M. Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Acad Emerg Med. 2018; 25: 261 - 266.